Today: 1 July 2026
ASE Technology stock (ASX) near a 52-week high as Fed and Big Tech earnings loom
26 January 2026
2 mins read

ASE Technology stock (ASX) near a 52-week high as Fed and Big Tech earnings loom

New York, Jan 25, 2026, 17:32 EST — The market has closed.

  • ASE Technology’s shares on the U.S. market ended at $19.39, marking a roughly 1.7% gain.
  • On Monday, markets reopen with attention on the Fed’s decision and mega-cap tech earnings, especially for AI-related suppliers.
  • ASE’s upcoming key event is the fourth-quarter earnings call scheduled for Feb. 5.

ASE Technology Holding Co., Ltd.’s shares traded on U.S. markets closed Friday close to their peak levels. Investors are now weighing potential catalysts ahead of Monday’s session.

This setup is crucial since ASE operates in the latter stages of the chip supply chain. Changes in demand for data-center and device chips directly impact its packaging and testing orders.

Investors brace for a week packed with a Federal Reserve meeting and a flood of large-cap tech earnings, all eyes on whether AI investments are starting to pay off. “Earnings are the driver,” said Franklin Templeton senior market strategist Chris Galipeau. Meanwhile, PNC chief investment strategist Yung-Yu Ma called the recent sessions a “short but steep roller-coaster ride.” Reuters

ASE’s American depositary receipts (ADRs) ended the session at $19.39, gaining 33 cents from the previous close. The shares have oscillated between $6.94 and $19.665 in the past year, pushing near the upper end of that band.

ASE ranks among the globe’s top players in chip packaging and testing—crucial stages that transform wafers into final chips and verify their performance. Its common stock is listed in Taiwan under ticker 3711, with ADRs available in New York trading as ASX.

Absent any company-specific news over the weekend, ASE investors are now focused on the upcoming fourth-quarter earnings call set for Feb. 5, per the company’s investor relations calendar.

That forecast is expected to raise questions about advanced packaging capacity and how quickly investments are being made. Investors will also want to know if clients are demanding greater testing and packaging throughput as they launch new chips for servers and premium devices.

Ahead of ASE’s earnings, investors are zeroing in on what Apple, Microsoft, Meta, and Tesla reveal about demand and AI-related capital spending. For firms like ASE, those insights often set the tone for order flow several months out, despite the connection being somewhat indirect.

The rate environment plays a key role. Packaging and test stocks often behave like growth names, so shifts in interest rates can reshape investor views on future earnings—particularly when these shares hover near their yearly highs.

The risk is clear: if big tech issues weak guidance and cuts back spending, suppliers across the semiconductor chain—from tools to packaging—could feel the impact. With the stock having rallied sharply, there’s little cushion for unexpected setbacks. On top of that, policy shifts and geopolitical tensions continue to rattle markets, injecting fresh uncertainty.

ASX investors will be watching closely on Feb. 5, when ASE releases its results and outlook. This comes amid ongoing weekly discussions about whether the AI trade is still driving genuine demand.

Khadija Saeed is a financial markets reporter at TS2.tech, specializing in stocks, technology and emerging industries. She studied economics and finance at the London School of Economics and previously worked in market research before moving into financial journalism. Her coverage focuses on the companies, innovations and economic trends influencing global investors.

Stock Market Today

  • ASX 200 trails global indexes in 2026 as key healthcare names dive
    July 1, 2026, 3:42 AM EDT. The ASX 200 barely managed a gain of less than 2.8% for the 2026 financial year, outpaced by major overseas markets. The rise was negative after inflation. US stocks soared, with the S&P 500 up 20.8%, NASDAQ up 28.7%, and Europe's STOXX 600 climbing 19%. Losses for CSL-off 52%-and Cochlear, down almost 60%, weighed on the Australian market. Bank results were mixed; ANZ gained 16% but Commonwealth Bank and NAB lagged. 4D Medical stood out with strong returns while the rest of the market barely moved.
Exxon stock price: XTO’s Eagle Ford sale push puts XOM in play ahead of key week
Previous Story

Exxon stock price: XTO’s Eagle Ford sale push puts XOM in play ahead of key week

AAPL stock jumps nearly 3% as Morgan Stanley flags iPhone 17 strength ahead of Apple earnings
Next Story

AAPL stock jumps nearly 3% as Morgan Stanley flags iPhone 17 strength ahead of Apple earnings

Go toTop